Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

DOI Full Paper Access

193

Citations

29

References

2011

Year

Timothy A. Yap, David Olmos, André T. Brunetto, Nina Tunariu, Jorge Barriuso, Ruth Riisnaes, Lorna Pope, J. W. Clark, P. Andrew Futreal, Michael Germuska,

Journal of Clinical Oncology

Abstract

ARQ 197 safely inhibited intratumoral c-MET signaling. Further clinical evaluation focusing on combination approaches, including an erlotinib combination in non-small-cell lung cancer, is ongoing.

References

	Year	Citations

Page 1